Explore MarketSpeaker's latest reporting, research, and expert analysis tagged with "biotech", collected in one continuously updated archive.
AstraZeneca and Bristol Myers Squibb have held discussions about a potential merger valued at more than $400 billion, a deal that would create one of the world’s largest pharmaceutical companies.
Enhanced Games shares plunged after the company’s first steroid-permitted sports event failed to meet expectations.
Eli Lilly will acquire Ajax Therapeutics for up to $2.3 billion, strengthening its pipeline in blood cancer treatments.
Novo Nordisk has partnered with OpenAI to enhance its drug discovery efforts using advanced AI tools, aiming to accelerate identification of new treatments.
Eli Lilly will pay up to $2.75 billion to bring AI-developed drugs from Insilico Medicine to market. The deal highlights growing momentum in AI-driven drug discovery.
Novartis has agreed to acquire immunology biotech Excellergy for $2 billion, marking its second major deal in a week. The move strengthens its pipeline in next-generation allergy treatments.
Leap Therapeutics shares jump 170% after rebranding to Cypherpunk and investing $50M in Zcash, marking a major shift toward digital asset strategy.
The Chan Zuckerberg Biohub, founded by Mark Zuckerberg and Priscilla Chan, announced a new initiative merging artificial intelligence, biology, and computing to accelerate breakthroughs in health and disease research.
Molecular-diagnostics startup BillionToOne raised $273 million in an oversubscribed IPO, with shares jumping 67% at debut and valuing the company at around $4.4 billion.